Hongbin Chi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongbin Chi has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Jie Qiao
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
10 shared publications Lin Zeng
Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing, China
9 shared publicationsLixue Chen
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
9 shared publicationsRong Li
Reproductive Medicine Center, Peking University Third Hospital, Beijing, China
9 shared publications- Lin Zeng
Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China
6 shared publications Ning Huang
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Haidian District, Beijing, People’s Republic of China
6 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 20
Effects of different ovulation induction protocols on pregnancy outcomes of fresh cycles in patients undergoing in vitro fertilization-embryo transfer with donor sperm
Objectives: This study analyzed clinical pregnancy outcomes in patients undergoing in vitro fertilization-embryo transfer with donor sperm (IVF-D) using different ovulation induction protocols, to provide reference data for selecting appropriate protocols. Methods: Data from 1801 cycles in patients who underwent IVF-D in Peking University Third Hospital between June 2010 and June 2021 were retrospectively analyzed. Participants were divided into three groups based on the controlled ovarian hyperstimulation protocol: follicular-phase ultralong gonadotropin-releasing hormone agonist (GnRH-a), luteal-phase GnRH-a long, and gonadotropin-releasing hormone antagonist (GnRH-ant) protocol groups. Results: Significant differences were observed among the groups in gonadotropin (Gn) starting dose, Gn administration duration, total Gn dose, estradiol level on the day of human chorionic gonadotropin (hCG) administration (hCG day), progesterone level on hCG day, luteinizing hormone level on hCG day, endometrial thickness on hCG day, and number of embryos transferred (p < 0.05). We also found significant group differences in the number of eggs retrieved, two pronucleizygotes, and cleavages (p < 0.05), but not in high-quality embryos (p < 0.05). Clinical pregnancy and live birth rates significantly differed among the three groups (p < 0.05), whereas ectopic pregnancy, early miscarriage, and multiple pregnancy rates did not (p < 0.05). Conclusion: In fresh embryo transfer cycles, the GnRH-ant protocol required the shortest duration of Gn administration and lowest total Gn dose, whereas the GnRH-a long protocol had the highest clinical pregnancy rate. Therefore, the GnRH-a long protocol is considered the preferred method for female patients who can undergo fresh transfers during IVF-D cycles.
- 8 January 2026
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 313 (1) , 20
Open AccessEffects of different ovulation induction protocols on pregnancy outcomes of fresh cycles in patients undergoing in vitro fertilization-embryo transfer with donor sperm
Objectives: This study analyzed clinical pregnancy outcomes in patients undergoing in vitro fertilization-embryo transfer with donor sperm (IVF-D) using different ovulation induction protocols, to provide reference data for selecting appropriate protocols. Methods: Data from 1801 cycles in patients who underwent IVF-D in Peking University Third Hospital between June 2010 and June 2021 were retrospectively analyzed. Participants were divided into three groups based on the controlled ovarian hyperstimulation protocol: follicular-phase ultralong gonadotropin-releasing hormone agonist (GnRH-a), luteal-phase GnRH-a long, and gonadotropin-releasing hormone antagonist (GnRH-ant) protocol groups. Results: Significant differences were observed among the groups in gonadotropin (Gn) starting dose, Gn administration duration, total Gn dose, estradiol level on the day of human chorionic gonadotropin (hCG) administration (hCG day), progesterone level on hCG day, luteinizing hormone level on hCG day, endometrial thickness on hCG day, and number of embryos transferred (p < 0.05). We also found significant group differences in the number of eggs retrieved, two pronucleizygotes, and cleavages (p < 0.05), but not in high-quality embryos (p < 0.05). Clinical pregnancy and live birth rates significantly differed among the three groups (p < 0.05), whereas ectopic pregnancy, early miscarriage, and multiple pregnancy rates did not (p < 0.05). Conclusion: In fresh embryo transfer cycles, the GnRH-ant protocol required the shortest duration of Gn administration and lowest total Gn dose, whereas the GnRH-a long protocol had the highest clinical pregnancy rate. Therefore, the GnRH-a long protocol is considered the preferred method for female patients who can undergo fresh transfers during IVF-D cycles.
- Open Access
- 5 December 2025
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 24 (1)
Congenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization
Background: Congenital anomalies are a critical public health concern and warrant prioritization in research. However, the teratogenic potential of dydrogesterone (DYG) remains uncertain and a subject of ongoing debate. Methods: This retrospective cohort study included patients undergoing embryo transfer between January 2010 and December 2018. It analyzed 124,815 embryo transfer cycles (80,103 [64.2%] fresh; 44,712 [35.8%] frozen), resulting in 52,175 live births. Newborns were stratified by maternal luteal phase support (DYG-exposed vs. unexposed). Patients with known congenital malformation risk factors were excluded. Congenital anomaly incidence was compared between groups. Stratified analysis and multivariate logistic regression models adjusting for confounders were employed. Results: The total congenital anomaly rate was significantly lower in DYG-exposed newborns compared to unexposed groups (6.05‰ vs. 7.90‰, P = 0.020), with particularly notable differences in musculoskeletal malformations (0.63‰ vs. 1.33‰, P = 0.025). No significant differences were observed in other congenital anomaly categories. After stratifying by fresh or frozen cycles, DYG-exposed and unexposed groups showed no significant differences in birth defects during fresh cycles. In frozen cycles, musculoskeletal anomalies were significantly lower in the DYG group both before (0.60‰ vs. 2.37‰, P = 0.020) and after adjustment ( P = 0.009, OR: 0.19, 95% CI: 0.05–0.66). Other anomaly categories remained unaffected. However, this specific association did not remain significant after rigorous correction for multiple testing with the application of both the Bonferroni and False Discovery Rate (FDR) methods. Multivariate analysis adjusted for confounders revealed no increased risk of congenital anomalies associated with DYG exposure. Conclusions: First-trimester dydrogesterone therapy was not associated with an increased risk of congenital anomalies. Due to the limitations of this cohort study, further follow-up and in-depth data analysis are planned for future studies.
- 5 December 2025
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 24 (1)
Open AccessCongenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization
Background: Congenital anomalies are a critical public health concern and warrant prioritization in research. However, the teratogenic potential of dydrogesterone (DYG) remains uncertain and a subject of ongoing debate. Methods: This retrospective cohort study included patients undergoing embryo transfer between January 2010 and December 2018. It analyzed 124,815 embryo transfer cycles (80,103 [64.2%] fresh; 44,712 [35.8%] frozen), resulting in 52,175 live births. Newborns were stratified by maternal luteal phase support (DYG-exposed vs. unexposed). Patients with known congenital malformation risk factors were excluded. Congenital anomaly incidence was compared between groups. Stratified analysis and multivariate logistic regression models adjusting for confounders were employed. Results: The total congenital anomaly rate was significantly lower in DYG-exposed newborns compared to unexposed groups (6.05‰ vs. 7.90‰, P = 0.020), with particularly notable differences in musculoskeletal malformations (0.63‰ vs. 1.33‰, P = 0.025). No significant differences were observed in other congenital anomaly categories. After stratifying by fresh or frozen cycles, DYG-exposed and unexposed groups showed no significant differences in birth defects during fresh cycles. In frozen cycles, musculoskeletal anomalies were significantly lower in the DYG group both before (0.60‰ vs. 2.37‰, P = 0.020) and after adjustment ( P = 0.009, OR: 0.19, 95% CI: 0.05–0.66). Other anomaly categories remained unaffected. However, this specific association did not remain significant after rigorous correction for multiple testing with the application of both the Bonferroni and False Discovery Rate (FDR) methods. Multivariate analysis adjusted for confounders revealed no increased risk of congenital anomalies associated with DYG exposure. Conclusions: First-trimester dydrogesterone therapy was not associated with an increased risk of congenital anomalies. Due to the limitations of this cohort study, further follow-up and in-depth data analysis are planned for future studies.
- Open Access
- 20 July 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 52 (2) , 105170
Impact of vitamin D deficiency on phenotypes and IVF outcomes in PCOS: a prospective study
- 20 July 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 52 (2) , 105170
Open AccessImpact of vitamin D deficiency on phenotypes and IVF outcomes in PCOS: a prospective study
- 15 May 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (7) , 1357-1365
SHR7280, an oral gonadotropin-releasing hormone antagonist, for the prevention of premature luteinizing hormone surge in controlled ovarian hyperstimulation: a dose-finding, phase 2 trial
STUDY QUESTION: What is the minimum effective dose of SHR7280, a novel oral GnRH antagonist, to prevent a premature LH surge in women undergoing controlled ovarian hyperstimulation for ART? SUMMARY ANSWER: SHR7280 at 200 mg once every 12 h (Q12h) was the minimal effective dose to suppress an LH surge and was associated with high-quality embryos, and a high clinical pregnancy rate. SHR7280 was well-tolerated and safe. WHAT IS KNOWN ALREADY: Currently, all approved GnRH antagonists for preventing a premature LH surge are injectable, peptide-based formulations, which can cause inconvenience and injection site reactions. There is a significant unmet need for an orally available GnRH antagonist to address this issue. SHR7280 has previously demonstrated effective suppression of LH levels in healthy volunteers in phase 1 trials. STUDY DESIGN, SIZE, DURATION: This multi-center, open-label, dosing-finding phase 2 trial was conducted between 26 January 2022 and 3 August 2023 in 85 infertile women. PARTICIPANTS/MATERIALS, SETTING, METHODS: The starting dose of SHR7280 was 300 mg Q12h, followed by dose exploration in two lower dose groups (200 mg Q12h and 200 mg Q24h) sequentially. Dose exploration was terminated if an LH surge occurred. SHR7280 was administrated orally starting on Day 5 of recombinant human FSH stimulation until hCG administration. The primary endpoint was the rate of premature LH surge inhibition during SHR7280 treatment. MAIN RESULTS AND THE ROLE OF CHANCE: Eighty-five patients received SHR7280: 300 mg Q12h, n = 40; 200 mg Q12h, n = 42; 200 mg Q24h, n = 3. The mean ( ± SD) duration of SHR7280 treatment was 5.7 ± 1.2, 5.7 ± 1.3, and 3.7 ± 0.6 days, respectively. The rate of LH surge inhibition was 99% (95% CI 94–100) in all patients, 100% (95% CI 91–100) in the 300 mg Q12h group, 100% (95% CI 92–100) in the 200 mg Q12h group, and 67% (95% CI 9–99) in the 200 mg Q24h group. Two hundred milligrams Q12h was established as the minimal effective dose. Embryological and pregnancy outcomes were comparable in the 300 and 200 mg Q12h groups. In the 200 mg Q12h group, the mean ( ± SD) number of oocytes retrieved per patient, two-pronucleate zygotes, and high-quality embryos was 10.7 ± 4.6, 6.9 ± 3.2, and 3.9 ± 2.6, respectively; among patients receiving fresh embryo transfer, 62% (95% CI 44–78) were tested positive for serum β-hCG and 53% (95% CI 35–70) were confirmed to be clinically pregnant per transfer. No spontaneous ovulation occurred on the day of oocyte retrieval. In all 85 patients, treatment-related adverse events were reported in 1 (1%; mild in severity) patient. LIMITATIONS, REASONS FOR CAUTION: The sample size was moderate and there was no standard peptide-based GnRH antagonist as a control group. Additionally, the performance of SHR7280 in specific populations, such as patients with diminished ovarian reserve and at high risk of OHSS, remains to be established. Further research is also needed to determine the recommended dose in patients with high BMI, intending for frozen embryo transfer, and using a GnRH agonist as trigger. Moreover, the study included only Chinese patients and allowed up to 2 embryos per transfer. The efficacy and safety of SHR7280 in other racial groups and regions require further investigation. WIDER IMPLICATIONS OF THE FINDINGS: Findings from this phase 2 trial suggest that an oral GnRH antagonist could be an effective alternative for preventing a premature LH surge in ART. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Jiangsu Hengrui Pharmaceuticals. Z.L., Yu.S., C.S., Hong.C., and K.S. were employees of Jiangsu Hengrui Pharmaceuticals at the time of study. All other authors have no conflicts of interests to declare. TRIAL REGISTRATION NUMBER: NCT05082233.
- 15 May 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (7) , 1357-1365
SHR7280, an oral gonadotropin-releasing hormone antagonist, for the prevention of premature luteinizing hormone surge in controlled ovarian hyperstimulation: a dose-finding, phase 2 trial
STUDY QUESTION: What is the minimum effective dose of SHR7280, a novel oral GnRH antagonist, to prevent a premature LH surge in women undergoing controlled ovarian hyperstimulation for ART? SUMMARY ANSWER: SHR7280 at 200 mg once every 12 h (Q12h) was the minimal effective dose to suppress an LH surge and was associated with high-quality embryos, and a high clinical pregnancy rate. SHR7280 was well-tolerated and safe. WHAT IS KNOWN ALREADY: Currently, all approved GnRH antagonists for preventing a premature LH surge are injectable, peptide-based formulations, which can cause inconvenience and injection site reactions. There is a significant unmet need for an orally available GnRH antagonist to address this issue. SHR7280 has previously demonstrated effective suppression of LH levels in healthy volunteers in phase 1 trials. STUDY DESIGN, SIZE, DURATION: This multi-center, open-label, dosing-finding phase 2 trial was conducted between 26 January 2022 and 3 August 2023 in 85 infertile women. PARTICIPANTS/MATERIALS, SETTING, METHODS: The starting dose of SHR7280 was 300 mg Q12h, followed by dose exploration in two lower dose groups (200 mg Q12h and 200 mg Q24h) sequentially. Dose exploration was terminated if an LH surge occurred. SHR7280 was administrated orally starting on Day 5 of recombinant human FSH stimulation until hCG administration. The primary endpoint was the rate of premature LH surge inhibition during SHR7280 treatment. MAIN RESULTS AND THE ROLE OF CHANCE: Eighty-five patients received SHR7280: 300 mg Q12h, n = 40; 200 mg Q12h, n = 42; 200 mg Q24h, n = 3. The mean ( ± SD) duration of SHR7280 treatment was 5.7 ± 1.2, 5.7 ± 1.3, and 3.7 ± 0.6 days, respectively. The rate of LH surge inhibition was 99% (95% CI 94–100) in all patients, 100% (95% CI 91–100) in the 300 mg Q12h group, 100% (95% CI 92–100) in the 200 mg Q12h group, and 67% (95% CI 9–99) in the 200 mg Q24h group. Two hundred milligrams Q12h was established as the minimal effective dose. Embryological and pregnancy outcomes were comparable in the 300 and 200 mg Q12h groups. In the 200 mg Q12h group, the mean ( ± SD) number of oocytes retrieved per patient, two-pronucleate zygotes, and high-quality embryos was 10.7 ± 4.6, 6.9 ± 3.2, and 3.9 ± 2.6, respectively; among patients receiving fresh embryo transfer, 62% (95% CI 44–78) were tested positive for serum β-hCG and 53% (95% CI 35–70) were confirmed to be clinically pregnant per transfer. No spontaneous ovulation occurred on the day of oocyte retrieval. In all 85 patients, treatment-related adverse events were reported in 1 (1%; mild in severity) patient. LIMITATIONS, REASONS FOR CAUTION: The sample size was moderate and there was no standard peptide-based GnRH antagonist as a control group. Additionally, the performance of SHR7280 in specific populations, such as patients with diminished ovarian reserve and at high risk of OHSS, remains to be established. Further research is also needed to determine the recommended dose in patients with high BMI, intending for frozen embryo transfer, and using a GnRH agonist as trigger. Moreover, the study included only Chinese patients and allowed up to 2 embryos per transfer. The efficacy and safety of SHR7280 in other racial groups and regions require further investigation. WIDER IMPLICATIONS OF THE FINDINGS: Findings from this phase 2 trial suggest that an oral GnRH antagonist could be an effective alternative for preventing a premature LH surge in ART. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Jiangsu Hengrui Pharmaceuticals. Z.L., Yu.S., C.S., Hong.C., and K.S. were employees of Jiangsu Hengrui Pharmaceuticals at the time of study. All other authors have no conflicts of interests to declare. TRIAL REGISTRATION NUMBER: NCT05082233.
- Open Access
- 28 January 2025
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 23 (1) , 1-9
High anti-Müllerian hormone level as a predictor of poor pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection: a retrospective cohort study
To study the correlation between anti-Müllerian hormone levels and pregnancy outcomes after in vitro fertilization/intracytoplasmic sperm injection in women with polycystic ovary syndrome, which remains controversial. This retrospective cohort study recruited 4,719 women with infertility and polycystic ovary syndrome aged 20–40 years who underwent treatment at the Reproductive Center of Peking University Third Hospital between February 2017 and June 2023. We divided the participants into three groups according to the 25th and 75th percentile cutoffs of serum anti-Müllerian hormone: low (≤ 4.98 ng/mL, n = 1,198), average (4.98 − 10.65 ng/mL, n = 2,346), and high (≥ 10.65 ng/mL, n = 1,175). Pregnancy outcomes included live birth rate, miscarriage rate, clinical pregnancy rate, and cumulative live birth rate. The live birth rate for fresh embryo transfer was 39.8%, 35.9%, and 30.4% in the low, average, and high anti-Müllerian hormone groups, respectively. The miscarriage rate was 11.3%, 17.1%, and 21.8% in the low, average, and high anti-Müllerian hormone groups, respectively. Significant intergroup differences were observed in the live birth rate (P = 0.017) and miscarriage rate (P = 0.018). No significant intergroup difference was observed in the clinical pregnancy rate (P = 0.204) or cumulative live birth rate (P = 0.423). After adjusting the confounders by multivariable logistic regression analysis, anti-Müllerian hormone was associated with decreased live birth rate in the high anti-Müllerian hormone group compared with that in the low anti-Müllerian hormone group (odds ratio: 0.629, 95% confidence interval: 0.460–0.860). Anti-Müllerian hormone was associated with increased miscarriage rate in the average and high anti-Müllerian hormone groups compared with that in the low anti-Müllerian hormone group (average vs. low: odds ratio: 1.592, 95% confidence interval: 1.017–2.490); high vs. low: odds ratio: 2.045, 95% confidence interval: 1.152–3.633). High anti-Müllerian hormone is a prognostic factor for reduced live birth rate after fresh embryo transfer in women with polycystic ovary syndrome aged 20–40 years undergoing in vitro fertilization/intracytoplasmic sperm injection, and is associated with increased miscarriage rate in these patients.
- 28 January 2025
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 23 (1) , 1-9
Open AccessHigh anti-Müllerian hormone level as a predictor of poor pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection: a retrospective cohort study
To study the correlation between anti-Müllerian hormone levels and pregnancy outcomes after in vitro fertilization/intracytoplasmic sperm injection in women with polycystic ovary syndrome, which remains controversial. This retrospective cohort study recruited 4,719 women with infertility and polycystic ovary syndrome aged 20–40 years who underwent treatment at the Reproductive Center of Peking University Third Hospital between February 2017 and June 2023. We divided the participants into three groups according to the 25th and 75th percentile cutoffs of serum anti-Müllerian hormone: low (≤ 4.98 ng/mL, n = 1,198), average (4.98 − 10.65 ng/mL, n = 2,346), and high (≥ 10.65 ng/mL, n = 1,175). Pregnancy outcomes included live birth rate, miscarriage rate, clinical pregnancy rate, and cumulative live birth rate. The live birth rate for fresh embryo transfer was 39.8%, 35.9%, and 30.4% in the low, average, and high anti-Müllerian hormone groups, respectively. The miscarriage rate was 11.3%, 17.1%, and 21.8% in the low, average, and high anti-Müllerian hormone groups, respectively. Significant intergroup differences were observed in the live birth rate (P = 0.017) and miscarriage rate (P = 0.018). No significant intergroup difference was observed in the clinical pregnancy rate (P = 0.204) or cumulative live birth rate (P = 0.423). After adjusting the confounders by multivariable logistic regression analysis, anti-Müllerian hormone was associated with decreased live birth rate in the high anti-Müllerian hormone group compared with that in the low anti-Müllerian hormone group (odds ratio: 0.629, 95% confidence interval: 0.460–0.860). Anti-Müllerian hormone was associated with increased miscarriage rate in the average and high anti-Müllerian hormone groups compared with that in the low anti-Müllerian hormone group (average vs. low: odds ratio: 1.592, 95% confidence interval: 1.017–2.490); high vs. low: odds ratio: 2.045, 95% confidence interval: 1.152–3.633). High anti-Müllerian hormone is a prognostic factor for reduced live birth rate after fresh embryo transfer in women with polycystic ovary syndrome aged 20–40 years undergoing in vitro fertilization/intracytoplasmic sperm injection, and is associated with increased miscarriage rate in these patients.
- Open Access
- 2 December 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (1) , 85-95
Assessing the uptake of infertility core outcome set in IVF randomized controlled trials
STUDY QUESTION: Do the infertility core outcome set and standardized definitions affect the outcome selection for randomized controlled trials, and what aspects should be further improved in the future? SUMMARY ANSWER: Intrauterine pregnancy demonstrated the highest uptake level, whereas others were low, especially in neonatal outcomes; as time progresses, the target sample size increases, and with prospective registration, the consistency between outcomes reported in registrations and infertility core outcome set improves significantly. WHAT IS KNOWN ALREADY: The infertility core outcome set, published on 30 November 2020, aims to standardize outcome reporting and prevent selective reporting bias; however, there is a paucity of research evaluating its actual adoption, which is crucial for the timely promotion of transparency, standardization, adjustment of development strategies, and efficient resource utilization. STUDY DESIGN, SIZE, DURATION: This cross-sectional study included 1673 eligible randomized controlled trial registrations for infertility in 18 registries from March 2004 to July 2024 based on registry entries. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 4625 infertility-related studies from 1 November 1999 to 26 July 2024 were retrieved in the World Health Organization International Clinical Trials Registry Platform. Finally, 1673 randomized controlled trial registrations were selected and divided into four period groups. Period, target sample size, prospective registration, blinding, support, and countries/regions were potential influencing factors. The consistency of outcomes, definitions, and standardized denominators of randomized controlled trial registry entries with the recommendations of the infertility core outcome set were the main outcomes. Independent retrieval, screening, data extraction, and consistency evaluations by two assessors and expert consultations were conducted to assess the uptake and potential influencing factors of the infertility core outcome set in randomized controlled trials involving infertile patients undergoing in vitro fertilization. MAIN RESULTS AND THE ROLE OF CHANCE: Results reveal that the reporting level in the pregnancy domain was significantly higher than that in the neonatal domain (13.6% vs 5.7%). Intrauterine pregnancy (66.9%), live birth (27.6%), and miscarriage (26.5%) had relatively high uptake levels. The uptake of most core outcomes and domains, as well as the total number of reported core outcomes, showed statistically significant differences based on period, target sample size, and prospective registration. Multivariable analyses supported the above finding. Reasons responsible for the results may be attributed to the lack of effective promotional measures, as well as the limited researcher awareness regarding this core outcome set. LIMITATIONS, REASONS FOR CAUTION: Some results in this study may have been influenced by the subjective judgment of the evaluators due to the complexity of the information in registries. WIDER IMPLICATIONS OF THE FINDINGS: Uptake of most core outcomes or domains is increasing but is not yet ideal. Moreover, the upward trend cannot be solely attributed to the publication of the infertility core outcome set. The key to promoting uptake is to thoroughly explore and recognize the factors that both facilitate and hinder the uptake of the infertility core outcome set, further expand and publicize the core outcome set, and foster multidisciplinary or multiple stakeholder cooperation. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Capital’s Funds for Health Improvement and Research (CFH 2024-2G-4097), as well as the special fund of Beijing Key Clinical Specialty Construction Project. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: http://www.comet-initiative.org/Studies/Details/3184
- 2 December 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (1) , 85-95
Open AccessAssessing the uptake of infertility core outcome set in IVF randomized controlled trials
STUDY QUESTION: Do the infertility core outcome set and standardized definitions affect the outcome selection for randomized controlled trials, and what aspects should be further improved in the future? SUMMARY ANSWER: Intrauterine pregnancy demonstrated the highest uptake level, whereas others were low, especially in neonatal outcomes; as time progresses, the target sample size increases, and with prospective registration, the consistency between outcomes reported in registrations and infertility core outcome set improves significantly. WHAT IS KNOWN ALREADY: The infertility core outcome set, published on 30 November 2020, aims to standardize outcome reporting and prevent selective reporting bias; however, there is a paucity of research evaluating its actual adoption, which is crucial for the timely promotion of transparency, standardization, adjustment of development strategies, and efficient resource utilization. STUDY DESIGN, SIZE, DURATION: This cross-sectional study included 1673 eligible randomized controlled trial registrations for infertility in 18 registries from March 2004 to July 2024 based on registry entries. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 4625 infertility-related studies from 1 November 1999 to 26 July 2024 were retrieved in the World Health Organization International Clinical Trials Registry Platform. Finally, 1673 randomized controlled trial registrations were selected and divided into four period groups. Period, target sample size, prospective registration, blinding, support, and countries/regions were potential influencing factors. The consistency of outcomes, definitions, and standardized denominators of randomized controlled trial registry entries with the recommendations of the infertility core outcome set were the main outcomes. Independent retrieval, screening, data extraction, and consistency evaluations by two assessors and expert consultations were conducted to assess the uptake and potential influencing factors of the infertility core outcome set in randomized controlled trials involving infertile patients undergoing in vitro fertilization. MAIN RESULTS AND THE ROLE OF CHANCE: Results reveal that the reporting level in the pregnancy domain was significantly higher than that in the neonatal domain (13.6% vs 5.7%). Intrauterine pregnancy (66.9%), live birth (27.6%), and miscarriage (26.5%) had relatively high uptake levels. The uptake of most core outcomes and domains, as well as the total number of reported core outcomes, showed statistically significant differences based on period, target sample size, and prospective registration. Multivariable analyses supported the above finding. Reasons responsible for the results may be attributed to the lack of effective promotional measures, as well as the limited researcher awareness regarding this core outcome set. LIMITATIONS, REASONS FOR CAUTION: Some results in this study may have been influenced by the subjective judgment of the evaluators due to the complexity of the information in registries. WIDER IMPLICATIONS OF THE FINDINGS: Uptake of most core outcomes or domains is increasing but is not yet ideal. Moreover, the upward trend cannot be solely attributed to the publication of the infertility core outcome set. The key to promoting uptake is to thoroughly explore and recognize the factors that both facilitate and hinder the uptake of the infertility core outcome set, further expand and publicize the core outcome set, and foster multidisciplinary or multiple stakeholder cooperation. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Capital’s Funds for Health Improvement and Research (CFH 2024-2G-4097), as well as the special fund of Beijing Key Clinical Specialty Construction Project. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: http://www.comet-initiative.org/Studies/Details/3184
- 16 November 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (12) , 3445-3453
Dual trigger versus human chorionic gonadotropin trigger for blastocyst quality and cumulative live birth
Purpose To evaluate the difference in the number of euploid blastocysts and cumulative live birth rate (LBR) between dual and human chorionic gonadotropin (hCG) triggers in poor and normal ovarian responders undergoing preimplantation genetic testing (PGT) cycles. Methods This retrospective cohort study was enrolled from July 2018 to December 2021 and followed up until June 2024 at a single reproductive medical center. Overall, 1040 in vitro fertilization (IVF)-PGT and 784 frozen-thawed embryo transfer (FET) cycles were assessed. Dual (triptorelin acetate 0.2 mg and recombinant hCG [rhCG] 250 µg) or hCG (rhCG 250 µg) trigger was used for oocyte maturation in the gonadotropin-releasing hormone antagonist protocol and PGT cycles. We assessed the embryo outcomes and FET cumulative pregnancy outcomes. Results The number of oocytes retrieved (10.17 ± 5.22 vs 10.27 ± 5.14, P = 0.789), MII oocytes (8.24 ± 4.26 vs 8.28 ± 4.05, P = 0.888), blastocysts (2.16 ± 1.50 vs 2.12 ± 1.49, P = 0.729), euploid blastocysts (1.06 ± 1.14 vs 1.09 ± 1.23, P = 0.726), and the rate of cumulative LBR (24.9% vs 24.9%, P = 1.000) in the dual trigger group were comparable with those in the hCG group. The trigger method was not correlated with higher LBR based on logistic regression analysis (odds ratio[OR] = 1.040 [0.778–1.392], P = 0.790). Conclusion For poor and normal ovarian responders, the dual trigger, compared with the hCG trigger, did not improve the PGT embryo outcomes and FET cumulative pregnancy outcomes.
- 16 November 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (12) , 3445-3453
Dual trigger versus human chorionic gonadotropin trigger for blastocyst quality and cumulative live birth
Purpose To evaluate the difference in the number of euploid blastocysts and cumulative live birth rate (LBR) between dual and human chorionic gonadotropin (hCG) triggers in poor and normal ovarian responders undergoing preimplantation genetic testing (PGT) cycles. Methods This retrospective cohort study was enrolled from July 2018 to December 2021 and followed up until June 2024 at a single reproductive medical center. Overall, 1040 in vitro fertilization (IVF)-PGT and 784 frozen-thawed embryo transfer (FET) cycles were assessed. Dual (triptorelin acetate 0.2 mg and recombinant hCG [rhCG] 250 µg) or hCG (rhCG 250 µg) trigger was used for oocyte maturation in the gonadotropin-releasing hormone antagonist protocol and PGT cycles. We assessed the embryo outcomes and FET cumulative pregnancy outcomes. Results The number of oocytes retrieved (10.17 ± 5.22 vs 10.27 ± 5.14, P = 0.789), MII oocytes (8.24 ± 4.26 vs 8.28 ± 4.05, P = 0.888), blastocysts (2.16 ± 1.50 vs 2.12 ± 1.49, P = 0.729), euploid blastocysts (1.06 ± 1.14 vs 1.09 ± 1.23, P = 0.726), and the rate of cumulative LBR (24.9% vs 24.9%, P = 1.000) in the dual trigger group were comparable with those in the hCG group. The trigger method was not correlated with higher LBR based on logistic regression analysis (odds ratio[OR] = 1.040 [0.778–1.392], P = 0.790). Conclusion For poor and normal ovarian responders, the dual trigger, compared with the hCG trigger, did not improve the PGT embryo outcomes and FET cumulative pregnancy outcomes.
- Open Access
- 13 November 2024
- Published by Springer Nature in Research Square
Congenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization: a retrospective cohort study
Congenital anomaly is a critical public health issue and should be a research priority. Here, 52,175 newborn babies conceived by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) in our reproductive center from 2010 to 2018 were studied. We found, in frozen cycles, the incidence of musculoskeletal anomalies was significantly lower in the dydrogesterone (DYG)-exposed group than that in the DYG-unexposed group, both before (0.60‰ vs. 2.37‰; P = 0.020) and after (OR: 0.19, 95% CI: 0.05–0.66) adjusting for confounders. The remaining classifications of congenital anomalies were not different between the groups in frozen cycles. In multivariate logistic regression analysis, first-trimester DYG therapy did not increase the risk of congenital anomalies. Due to the limitations of this cohort study, further follow-up and in-depth data analysis are planned for future studies.
- 13 November 2024
- Published by Springer Nature in Research Square
Open AccessCongenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization: a retrospective cohort study
Congenital anomaly is a critical public health issue and should be a research priority. Here, 52,175 newborn babies conceived by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) in our reproductive center from 2010 to 2018 were studied. We found, in frozen cycles, the incidence of musculoskeletal anomalies was significantly lower in the dydrogesterone (DYG)-exposed group than that in the DYG-unexposed group, both before (0.60‰ vs. 2.37‰; P = 0.020) and after (OR: 0.19, 95% CI: 0.05–0.66) adjusting for confounders. The remaining classifications of congenital anomalies were not different between the groups in frozen cycles. In multivariate logistic regression analysis, first-trimester DYG therapy did not increase the risk of congenital anomalies. Due to the limitations of this cohort study, further follow-up and in-depth data analysis are planned for future studies.
- 24 June 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (6) , 764-773
Intracytoplasmic Sperm Injection Versus In vitro Fertilization in Infertile Women with Thyroid Autoimmunity
Background: It has been reported that intracytoplasmic sperm injection (ICSI) may be the preferred fertilization method for women with thyroid autoimmunity (TAI) seeking assisted reproduction. We compared the reproductive outcomes of women with TAI who were treated with ICSI compared with in vitro fertilization (IVF). Methods: In this retrospective cohort study, we included women with infertility who were referred to the Reproductive Centre of Peking University Third Hospital for their first IVF/ICSI and embryo transfer (ET) treatment cycle from January 2019 to February 2021. In total, 2171 and 743 women with TAI underwent IVF and ICSI, respectively, while 8702 and 2668 women without TAI underwent IVF and ICSI, respectively. We examined the cumulative live birth rate (primary outcome) from the initiated stimulative cycle as well as the secondary outcomes of fertilization rate, rates of clinical pregnancy, and live birth after the first ET cycle. We compared the reproductive outcomes of women treated with IVF and ICSI according to TAI status. Multivariable logistic regression analyses were performed to adjust for relevant confounders. Results: Women who underwent ICSI had significantly higher fertilization rates than those who underwent IVF (median [interquartile range]: 0.6 [0.5–0.8] in the TAI-positive and IVF group vs. 0.7 [0.5–0.8] in the TAI-positive and ICSI group vs. 0.6 [0.5–0.8] the TAI-negative and IVF group vs. 0.7 [0.5–0.8] in the TAI-negative and ICSI group, p < 0.001). However, the rates of cumulative live births, clinical pregnancies, and live births were significantly lower among women with TAI who underwent ICSI than those who underwent IVF (cumulative live birth: 51.8% vs. 47%, adjusted odds ratio [aOR]: 0.80 [confidence interval, CI: 0.67–0.97]; clinical pregnancy: 43.0% vs. 38.8%, aOR: 0.81 [CI: 0.67–0.97]; live birth: 36.2% vs. 32.4%, aOR: 0.81 [CI: 0.66–0.98]). Conclusion: We observed that the use of ICSI in women with TAI was not associated with better assisted reproductive outcomes compared with IVF. Further prospective clinical trials are needed to confirm our findings.
- 24 June 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (6) , 764-773
Intracytoplasmic Sperm Injection Versus In vitro Fertilization in Infertile Women with Thyroid Autoimmunity
Background: It has been reported that intracytoplasmic sperm injection (ICSI) may be the preferred fertilization method for women with thyroid autoimmunity (TAI) seeking assisted reproduction. We compared the reproductive outcomes of women with TAI who were treated with ICSI compared with in vitro fertilization (IVF). Methods: In this retrospective cohort study, we included women with infertility who were referred to the Reproductive Centre of Peking University Third Hospital for their first IVF/ICSI and embryo transfer (ET) treatment cycle from January 2019 to February 2021. In total, 2171 and 743 women with TAI underwent IVF and ICSI, respectively, while 8702 and 2668 women without TAI underwent IVF and ICSI, respectively. We examined the cumulative live birth rate (primary outcome) from the initiated stimulative cycle as well as the secondary outcomes of fertilization rate, rates of clinical pregnancy, and live birth after the first ET cycle. We compared the reproductive outcomes of women treated with IVF and ICSI according to TAI status. Multivariable logistic regression analyses were performed to adjust for relevant confounders. Results: Women who underwent ICSI had significantly higher fertilization rates than those who underwent IVF (median [interquartile range]: 0.6 [0.5–0.8] in the TAI-positive and IVF group vs. 0.7 [0.5–0.8] in the TAI-positive and ICSI group vs. 0.6 [0.5–0.8] the TAI-negative and IVF group vs. 0.7 [0.5–0.8] in the TAI-negative and ICSI group, p < 0.001). However, the rates of cumulative live births, clinical pregnancies, and live births were significantly lower among women with TAI who underwent ICSI than those who underwent IVF (cumulative live birth: 51.8% vs. 47%, adjusted odds ratio [aOR]: 0.80 [confidence interval, CI: 0.67–0.97]; clinical pregnancy: 43.0% vs. 38.8%, aOR: 0.81 [CI: 0.67–0.97]; live birth: 36.2% vs. 32.4%, aOR: 0.81 [CI: 0.66–0.98]). Conclusion: We observed that the use of ICSI in women with TAI was not associated with better assisted reproductive outcomes compared with IVF. Further prospective clinical trials are needed to confirm our findings.
- Open Access
- 2 April 2024
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 24 (1) , 1-9
Impact of thyroid autoimmunity on the cumulative live birth rates after IVF/ICSI treatment cycles
Background: Cumulative live birth rate (CLBR) is considered as the most important endpoint for assessing the probability of having a baby in a complete in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment cycle. Many previous studies have focused on the association between thyroid autoimmunity (TAI) and live birth rate after first embryo transfer cycle, however, evidence on whether the presence of TAI affects the CLBR is lacking. The purpose of this study is to investigate the impact of TAI on the CLBR in a complete IVF/ICSI cycle. Methods: This retrospective study included 12,796 women who underwent their first IVF/ICSI treatment between January 2019 and February 2021. Based on the levels of thyroid antibodies, 2,603 women were assigned to the TAI group, and 10,193 women were assigned to the control group. Subgroup analysis was performed according to the different causes of infertility (including male factor only, ovulation disorder, tubal factor, endometriosis and unexplained infertility) and different types and titres of thyroid antibodies. The primary outcome in this study was CLBR, which included live births from the fresh embryo transfer cycle and all subsequent frozen-thawed embryo transfer cycles performed before December 2021. Results: There was no significant difference in the CLBR between the TAI and control groups, even after adjusting for relevant confounders including age, body mass index, cause of infertility, thyroid function, protocols of controlled ovarian stimulation, type of transfer (fresh vs. frozen), type of transferred embryo (cleavage-stage embryo vs. blastocyst), and fertilization method (IVF vs. ICSI) (cumulative live birth: 50.6% vs. 52.1%, OR 0.94, 95% CI 0.86–1.02, adjusted OR 0.97, 95%CI 0.89–1.06). Subgroup analysis showed that no significant difference was observed in CLBR between the TAI and control groups for all causes of infertility, except for infertility attributed to endometriosis. Among women with endometriosis, the CLBR was significantly lower in the TAI group than that in the control group; however, this difference was not significant after adjusting for potential confounders including age, body mass index, thyroid function, protocols of controlled ovarian stimulation, type of transfer (fresh vs. frozen), type of transferred embryo (cleavage-stage embryo vs. blastocyst), and fertilization method (IVF vs. ICSI) (cumulative live births: 43.1% vs. 51.0%, OR 0.73, 95% CI 0.53–0.99, adjusted OR 0.74, 95% CI 0.53–1.02). Another subgroup analysis demonstrated that the type and titre of thyroid antibody did not affect CLBR in women with TAI. Conclusions: In our study, there was no significant difference in the CLBR between women with TAI and those without TAI, which suggests that TAI did not affect the chances of having a baby in a complete IVF/ICSI treatment cycle.
- 2 April 2024
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 24 (1) , 1-9
Open AccessImpact of thyroid autoimmunity on the cumulative live birth rates after IVF/ICSI treatment cycles
Background: Cumulative live birth rate (CLBR) is considered as the most important endpoint for assessing the probability of having a baby in a complete in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment cycle. Many previous studies have focused on the association between thyroid autoimmunity (TAI) and live birth rate after first embryo transfer cycle, however, evidence on whether the presence of TAI affects the CLBR is lacking. The purpose of this study is to investigate the impact of TAI on the CLBR in a complete IVF/ICSI cycle. Methods: This retrospective study included 12,796 women who underwent their first IVF/ICSI treatment between January 2019 and February 2021. Based on the levels of thyroid antibodies, 2,603 women were assigned to the TAI group, and 10,193 women were assigned to the control group. Subgroup analysis was performed according to the different causes of infertility (including male factor only, ovulation disorder, tubal factor, endometriosis and unexplained infertility) and different types and titres of thyroid antibodies. The primary outcome in this study was CLBR, which included live births from the fresh embryo transfer cycle and all subsequent frozen-thawed embryo transfer cycles performed before December 2021. Results: There was no significant difference in the CLBR between the TAI and control groups, even after adjusting for relevant confounders including age, body mass index, cause of infertility, thyroid function, protocols of controlled ovarian stimulation, type of transfer (fresh vs. frozen), type of transferred embryo (cleavage-stage embryo vs. blastocyst), and fertilization method (IVF vs. ICSI) (cumulative live birth: 50.6% vs. 52.1%, OR 0.94, 95% CI 0.86–1.02, adjusted OR 0.97, 95%CI 0.89–1.06). Subgroup analysis showed that no significant difference was observed in CLBR between the TAI and control groups for all causes of infertility, except for infertility attributed to endometriosis. Among women with endometriosis, the CLBR was significantly lower in the TAI group than that in the control group; however, this difference was not significant after adjusting for potential confounders including age, body mass index, thyroid function, protocols of controlled ovarian stimulation, type of transfer (fresh vs. frozen), type of transferred embryo (cleavage-stage embryo vs. blastocyst), and fertilization method (IVF vs. ICSI) (cumulative live births: 43.1% vs. 51.0%, OR 0.73, 95% CI 0.53–0.99, adjusted OR 0.74, 95% CI 0.53–1.02). Another subgroup analysis demonstrated that the type and titre of thyroid antibody did not affect CLBR in women with TAI. Conclusions: In our study, there was no significant difference in the CLBR between women with TAI and those without TAI, which suggests that TAI did not affect the chances of having a baby in a complete IVF/ICSI treatment cycle.